An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGal in Patients With Fabry Disease
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Alpha galactosidase (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Greenovation Biotech
- 12 Dec 2017 Status changed from recruiting to completed.
- 31 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.
- 31 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Oct 2017.